<div class="elementor-post__thumbnail elementor-fit-height imagem_injetada" style="margin-bottom:7px; display:none;"><img width="300" height="168" src="https://www.femama.org.br/site_old/_files/noticia/3587/5c98c48607daa.jpg" class="attachment-medium size-medium" alt=""></div><div class="elementor-post__thumbnail elementor-fit-height imagem_injetada" style="margin-bottom:7px; display:none;"><img width="300" height="168" src="https://www.femama.org.br/site_old/_files/noticia/3587/5c98c48607daa.jpg" class="attachment-medium size-medium" alt=""></div>{"id":20063,"date":"2019-03-25T00:00:00","date_gmt":"2019-03-25T03:00:00","guid":{"rendered":"https:\/\/femama.org.br\/site_novo\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/"},"modified":"2019-03-25T00:00:00","modified_gmt":"2019-03-25T03:00:00","slug":"anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico","status":"publish","type":"post","link":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/","title":{"rendered":"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico"},"content":{"rendered":"<p style=\"text-align: justify;\">A <a href=\"http:\/\/portal.anvisa.gov.br\/\" target=\"_blank\" rel=\"noopener\">Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria (ANVISA)<\/a> publicou o registro do medicamento abemaciclibe, indicado para o tratamento de pacientes adultos com c&acirc;ncer de mama avan&ccedil;ado ou metast&aacute;tico, com receptor hormonal positivo e receptor do fator de crescimento humano epid&eacute;rmico 2 negativo.<\/p>\n<p style=\"text-align: justify;\">Lan&ccedil;ado nos Estados Unidos em 2017 e aprovado na Europa e no Jap&atilde;o em 2018, o Brasil &eacute; o primeiro pa&iacute;s da Am&eacute;rica Latina a contar com a nova op&ccedil;&atilde;o terap&ecirc;utica, cujo lan&ccedil;amento deve ocorrer no segundo trimestre de 2019.<br \/>O tratamento oral &eacute; indicado em combina&ccedil;&atilde;o com um inibidor da aromatase como terapia end&oacute;crina inicial, em combina&ccedil;&atilde;o com fulvestranto como terapia end&oacute;crina inicial ou ap&oacute;s terapia end&oacute;crina. Tamb&eacute;m pode ser administrado sozinho, ap&oacute;s progress&atilde;o da doen&ccedil;a depois do uso de terapia end&oacute;crina e quimioter&aacute;picos anteriores para doen&ccedil;a metast&aacute;tica.<\/p>\n<p style=\"text-align: justify;\">A seguran&ccedil;a e efic&aacute;cia de abemaciclibe como tratamento aut&ocirc;nomo foram analisadas em um estudo com 132 pacientes com c&acirc;ncer de mama HR+ para HER2- que progrediu ap&oacute;s tratamento com terapia end&oacute;crina e quimioterapia ap&oacute;s o c&acirc;ncer ter se tornado metast&aacute;tico. O estudo mediu o percentual de pacientes cujos tumores diminu&iacute;ram total ou parcialmente ap&oacute;s o tratamento.<\/p>\n<p style=\"text-align: justify;\"><strong>Como funciona o tratamento<\/strong><\/p>\n<p style=\"text-align: justify;\">O abemaciclibe &eacute; um inibidor das enzimas CDK4 e CDK6 utilizado para o tratamento do subtipo mais comum de c&acirc;ncer de mama metast&aacute;tico, chamado HR+\/HER2- (receptor hormonal positivo\/receptor do fator de crescimento epid&eacute;rmico humano 2 negativo). O medicamento atua no bloqueio das enzimas envolvidas no crescimento de c&eacute;lulas com c&acirc;ncer.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/panoramafarmaceutico.com.br\/2019\/03\/22\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/%20\" target=\"_blank\" rel=\"noopener\"><strong>Com informa&ccedil;&otilde;es de Panorama Farmac&ecirc;utico, 22\/03\/2019<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A ANVISA publicou o registro do medicamento abemaciclibe, indicado para o tratamento de pacientes adultos com c&acirc;ncer de mama avan&ccedil;ado ou metast&aacute;tico, com receptor hormonal positivo e receptor do fator de crescimento humano epid&eacute;rmico 2 negativo.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[18,13],"tags":[],"class_list":["post-20063","post","type-post","status-publish","format-standard","hentry","category-cancer-de-mama","category-noticias-recentes"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico | FEMAMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico | FEMAMA\" \/>\n<meta property=\"og:description\" content=\"A ANVISA publicou o registro do medicamento abemaciclibe, indicado para o tratamento de pacientes adultos com c&acirc;ncer de mama avan&ccedil;ado ou metast&aacute;tico, com receptor hormonal positivo e receptor do fator de crescimento humano epid&eacute;rmico 2 negativo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/\" \/>\n<meta property=\"og:site_name\" content=\"FEMAMA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/femamabrasil\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-25T03:00:00+00:00\" \/>\n<meta name=\"author\" content=\"gabriel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@femama_\" \/>\n<meta name=\"twitter:site\" content=\"@femama_\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"gabriel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/\"},\"author\":{\"name\":\"gabriel\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#\\\/schema\\\/person\\\/b29142fa397d7b6b81efc40a77b11cc8\"},\"headline\":\"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico\",\"datePublished\":\"2019-03-25T03:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#organization\"},\"articleSection\":[\"C\u00e2ncer de Mama\",\"Not\u00edcias recentes\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/\",\"url\":\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/\",\"name\":\"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico | FEMAMA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#website\"},\"datePublished\":\"2019-03-25T03:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/noticias-recentes\\\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/femama.org.br\\\/site\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#website\",\"url\":\"https:\\\/\\\/femama.org.br\\\/site\\\/\",\"name\":\"FEMAMA\",\"description\":\"Federa\u00e7\u00e3o Brasileira de Institui\u00e7\u00f5es Filantr\u00f3picas de Apoio \u00e0 Sa\u00fade da Mama | C\u00e2ncer de mama\",\"publisher\":{\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/femama.org.br\\\/site\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#organization\",\"name\":\"Femama | Federa\u00e7\u00e3o Brasileira de Institui\u00e7\u00f5es Filantr\u00f3picas de Apoio \u00e0 Sa\u00fade da Mama | C\u00e2ncer de mama\",\"url\":\"https:\\\/\\\/femama.org.br\\\/site\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/femama.org.br\\\/site\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/logotipo-femama-horizontal.png\",\"contentUrl\":\"https:\\\/\\\/femama.org.br\\\/site\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/logotipo-femama-horizontal.png\",\"width\":300,\"height\":92,\"caption\":\"Femama | Federa\u00e7\u00e3o Brasileira de Institui\u00e7\u00f5es Filantr\u00f3picas de Apoio \u00e0 Sa\u00fade da Mama | C\u00e2ncer de mama\"},\"image\":{\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/femamabrasil\",\"https:\\\/\\\/x.com\\\/femama_\",\"https:\\\/\\\/www.instagram.com\\\/femama.brasil\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/femamaorg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/femama.org.br\\\/site\\\/#\\\/schema\\\/person\\\/b29142fa397d7b6b81efc40a77b11cc8\",\"name\":\"gabriel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c92f9be1169f04ec9350f2fbdf2115001e1c34eff29c7df9aea9b4eb22a84e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c92f9be1169f04ec9350f2fbdf2115001e1c34eff29c7df9aea9b4eb22a84e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c92f9be1169f04ec9350f2fbdf2115001e1c34eff29c7df9aea9b4eb22a84e?s=96&d=mm&r=g\",\"caption\":\"gabriel\"},\"sameAs\":[\"https:\\\/\\\/gabrielpiziolo.com.br\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico | FEMAMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/","og_locale":"pt_BR","og_type":"article","og_title":"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico | FEMAMA","og_description":"A ANVISA publicou o registro do medicamento abemaciclibe, indicado para o tratamento de pacientes adultos com c&acirc;ncer de mama avan&ccedil;ado ou metast&aacute;tico, com receptor hormonal positivo e receptor do fator de crescimento humano epid&eacute;rmico 2 negativo.","og_url":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/","og_site_name":"FEMAMA","article_publisher":"https:\/\/www.facebook.com\/femamabrasil","article_published_time":"2019-03-25T03:00:00+00:00","author":"gabriel","twitter_card":"summary_large_image","twitter_creator":"@femama_","twitter_site":"@femama_","twitter_misc":{"Escrito por":"gabriel","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/#article","isPartOf":{"@id":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/"},"author":{"name":"gabriel","@id":"https:\/\/femama.org.br\/site\/#\/schema\/person\/b29142fa397d7b6b81efc40a77b11cc8"},"headline":"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico","datePublished":"2019-03-25T03:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/femama.org.br\/site\/#organization"},"articleSection":["C\u00e2ncer de Mama","Not\u00edcias recentes"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/","url":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/","name":"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico | FEMAMA","isPartOf":{"@id":"https:\/\/femama.org.br\/site\/#website"},"datePublished":"2019-03-25T03:00:00+00:00","breadcrumb":{"@id":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/femama.org.br\/site\/noticias-recentes\/anvisa-aprova-novo-tratamento-oral-para-cancer-de-mama-avancado-ou-metastatico\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/femama.org.br\/site\/"},{"@type":"ListItem","position":2,"name":"ANVISA aprova novo tratamento oral para c\u00e2ncer de mama avan\u00e7ado ou metast\u00e1tico"}]},{"@type":"WebSite","@id":"https:\/\/femama.org.br\/site\/#website","url":"https:\/\/femama.org.br\/site\/","name":"FEMAMA","description":"Federa\u00e7\u00e3o Brasileira de Institui\u00e7\u00f5es Filantr\u00f3picas de Apoio \u00e0 Sa\u00fade da Mama | C\u00e2ncer de mama","publisher":{"@id":"https:\/\/femama.org.br\/site\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/femama.org.br\/site\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/femama.org.br\/site\/#organization","name":"Femama | Federa\u00e7\u00e3o Brasileira de Institui\u00e7\u00f5es Filantr\u00f3picas de Apoio \u00e0 Sa\u00fade da Mama | C\u00e2ncer de mama","url":"https:\/\/femama.org.br\/site\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/femama.org.br\/site\/#\/schema\/logo\/image\/","url":"https:\/\/femama.org.br\/site\/wp-content\/uploads\/2021\/12\/logotipo-femama-horizontal.png","contentUrl":"https:\/\/femama.org.br\/site\/wp-content\/uploads\/2021\/12\/logotipo-femama-horizontal.png","width":300,"height":92,"caption":"Femama | Federa\u00e7\u00e3o Brasileira de Institui\u00e7\u00f5es Filantr\u00f3picas de Apoio \u00e0 Sa\u00fade da Mama | C\u00e2ncer de mama"},"image":{"@id":"https:\/\/femama.org.br\/site\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/femamabrasil","https:\/\/x.com\/femama_","https:\/\/www.instagram.com\/femama.brasil\/","https:\/\/www.youtube.com\/user\/femamaorg"]},{"@type":"Person","@id":"https:\/\/femama.org.br\/site\/#\/schema\/person\/b29142fa397d7b6b81efc40a77b11cc8","name":"gabriel","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/e4c92f9be1169f04ec9350f2fbdf2115001e1c34eff29c7df9aea9b4eb22a84e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e4c92f9be1169f04ec9350f2fbdf2115001e1c34eff29c7df9aea9b4eb22a84e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e4c92f9be1169f04ec9350f2fbdf2115001e1c34eff29c7df9aea9b4eb22a84e?s=96&d=mm&r=g","caption":"gabriel"},"sameAs":["https:\/\/gabrielpiziolo.com.br"]}]}},"_links":{"self":[{"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/posts\/20063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/comments?post=20063"}],"version-history":[{"count":0,"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/posts\/20063\/revisions"}],"wp:attachment":[{"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/media?parent=20063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/categories?post=20063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/femama.org.br\/site\/wp-json\/wp\/v2\/tags?post=20063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}